Abstract:BACKGROUND:Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have garnered considerable attention as prospective modalities of treatment for liver fibrosis (LF). The inhibition of hepatic stellate cell (HSC) activation underlies the anti-fibrotic effects of hUC-MSCs. However, the precise mechanism by which hUC-MSCs impede HSC activation remains unclarified. We aimed to elucidate the intrinsic mechanisms underlying the therapeutic effects of hUC-MSCs in LF patients.METHODS:Mice with liver cirrhosis induced by carbon tetrachloride (CCl4) were used as experimental models and administered hUC-MSCs via tail-vein injection. The alterations in inflammation and fibrosis were evaluated through histopathological examinations. RNA sequencing (RNA-seq) and bioinformatics analysis were then conducted to investigate the therapeutic mechanism of hUC-MSCs. Finally, an in-vitro experiment involving the co-cultivation of hUC-MSCs or hUC-MSC-derived exosomes (MSC-Exos) with LX2 cells was performed to validate the potential mechanism underlying the hepatoprotective effects of hUC-MSCs in LF patients.RESULTS:hUC-MSC therapy significantly improved liver function and alleviated LF in CCl4-induced mice. High-throughput RNA-Seq analysis identified 1142 differentially expressed genes that were potentially involved in mediating the therapeutic effects of hUC-MSCs. These genes play an important role in regulating the extracellular matrix. miRNA expression data (GSE151098) indicated that the miR-148a-5p level was downregulated in LF samples, but restored following hUC-MSC treatment. miR-148a-5p was delivered to LX2 cells by hUC-MSCs via the exosome pathway, and the upregulated expression of miR-148a-5p significantly suppressed the expression of the activated phenotype of LX2 cells. SLIT3 was identified within the pool of potential target genes regulated by miR-148a-5p. Furthermore, hUC-MSC administration upregulated the expression of miR-148a-5p, which played a crucial role in suppressing the expression of SLIT3, thereby palliating fibrosis.CONCLUSIONS:hUC-MSCs inhibit the activation of HSCs through the miR-148a-5p/SLIT3 pathway and are thus capable of alleviating LF.

MicroRNA-214 Promotes Hepatic Stellate Cell Activation and Liver Fibrosis by Suppressing Sufu Expression

MicroRNA-101 Suppresses Liver Fibrosis by Downregulating PI3K/Akt/mTOR Signaling Pathway

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

MicroRNA-146b Regulates Hepatic Stellate Cell Activation Via Targeting of KLF4.

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7.

Oxidative stress promotes liver fibrosis by modulating the microRNA-144 and SIN3A-p38 pathways in hepatic stellate cells

miRNA‐130b‐5p promotes hepatic stellate cell activation and the development of liver fibrosis by suppressing SIRT4 expression

Human Umbilical Cord Mesenchymal Stem Cells Inhibit Liver Fibrosis Via the Microrna-148A-5p/slit3 Axis

HSC-derived exosomal miR-199a-5p promotes HSC activation and hepatocyte EMT via targeting SIRT1 in hepatic fibrosis

Inhibition of miR‐188‐5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway

Mir-654-5p Contributes to the Activation and Proliferation of Hepatic Stellate Cells by Targeting RXRα

MircoRNA-145 Promotes Activation of Hepatic Stellate Cells Via Targeting Krüppel-Like Factor 4

MiR-34c promotes hepatic stellate cell activation and Liver Fibrogenesis by suppressing ACSL1 expression.

MicroRNA-195-3p promotes hepatic stellate cell activation and liver fibrosis by suppressing PTEN expression

MicroRNA-194 Inactivates Hepatic Stellate Cells and Alleviates Liver Fibrosis by Inhibiting AKT2.

Identification of Liver Fibrosis-Related MicroRNAs in Human Primary Hepatic Stellate Cells Using High-Throughput Sequencing

MicroRNA-708 Represses Hepatic Stellate Cells Activation and Proliferation by Targeting ZEB1 Through Wnt/β-catenin Pathway.

miR-200c Accelerates Hepatic Stellate Cell-Induced Liver Fibrosis via Targeting the FOG2/PI3K Pathway

The miR-23b/27b/24-1 Cluster Inhibits Hepatic Fibrosis by Inactivating Hepatic Stellate Cells